

### Patient Information\*

Collection date: \_\_\_\_\_ Time: \_\_\_\_\_ : \_\_\_\_\_ A.M./P.M.

Name (last, first, middle initial): \_\_\_\_\_ Sex:  Male  Female

Date of birth (MM/DD/YYYY): \_\_\_\_\_

*\*\*Include copies of the patient's demographic face sheet.\*\**

Medical record/Patient ID#: \_\_\_\_\_

### Billing Information\*

**\*\*You MUST include copies of the patient's demographics sheet and both sides of the patient's insurance card(s), along with any secondary insurance information (if applicable), with this requisition.\*\***

### Provider Information

Ordering physician: \_\_\_\_\_

Ordering physician NPI #: \_\_\_\_\_

Duplicate report sent to: \_\_\_\_\_

Phone #: \_\_\_\_\_ Fax #: \_\_\_\_\_

### Clinical/Laboratory Information (Check all that apply.)

- |                                           |                                                            |                                                  |
|-------------------------------------------|------------------------------------------------------------|--------------------------------------------------|
| <input type="checkbox"/> Anemia           | <input type="checkbox"/> Leukopenia                        | <input type="checkbox"/> Thrombocytopenia        |
| <input type="checkbox"/> Leukocytosis     | <input type="checkbox"/> Lymphocytosis                     | <input type="checkbox"/> Abnormal cells on smear |
| <input type="checkbox"/> Lymphadenopathy  | <input type="checkbox"/> Mass                              | <input type="checkbox"/> Skin lesion             |
| <input type="checkbox"/> Serosal effusion | <input type="checkbox"/> Splenomegaly                      | <input type="checkbox"/> Hepatomegaly            |
| <input type="checkbox"/> Bone lesions     | <input type="checkbox"/> Ser/Urine abnormal immunoglobulin |                                                  |
- Other: \_\_\_\_\_

### Clinical History (Check all that apply.)

- Lymphoma Type: \_\_\_\_\_
- MDS/MPD Type: \_\_\_\_\_
- Leukemia Type: \_\_\_\_\_
- Plasma cell myeloma/MGUS: \_\_\_\_\_
- Other: \_\_\_\_\_
- EPO/Epogen/Procrit treatment
- G-CSF/Neupogen/Filgrastim treatment
- Post-therapy | Days: \_\_\_\_\_  Post-transplant | Days: \_\_\_\_\_

### Specimen Information

Date collected: \_\_\_\_\_ Time collected: \_\_\_\_\_

Bone marrow:  Aspirate  Biopsy  Clot

Peripheral blood  FNA Site: \_\_\_\_\_

Solid tissue (fresh) Site: \_\_\_\_\_

Solid tissue (fixed) Site: \_\_\_\_\_

Other: \_\_\_\_\_

### Flow Cytometry Studies

- |                                                                     |                                                     |
|---------------------------------------------------------------------|-----------------------------------------------------|
| <input type="checkbox"/> Flow for bone marrow <u>without</u> biopsy | <input type="checkbox"/> Flow DNA (ploidy, S-phase) |
| <input type="checkbox"/> Flow for bone marrow <u>with</u> biopsy    | <input type="checkbox"/> PNH                        |
| <input type="checkbox"/> Flow for peripheral blood                  | <input type="checkbox"/> Reflex CD38/ZAP-70 (CLL)   |
| <input type="checkbox"/> Flow for tissue/body fluid                 |                                                     |

### Molecular Pathology Studies

- #### Hematopathology
- |                                                                           |                                              |
|---------------------------------------------------------------------------|----------------------------------------------|
| <input type="checkbox"/> T-cell clonality                                 | <input type="checkbox"/> B-cell clonality    |
| <input type="checkbox"/> BCL2 gene rearrangement                          | <input type="checkbox"/> JAK2 V617f mutation |
| <input type="checkbox"/> JAK2 exon 12 mutation (reflex if V617f-negative) |                                              |
| <input type="checkbox"/> BCR-ABL gene rearrangement quantitative          |                                              |
| <input type="checkbox"/> BCR-ABL kinase domain mutations                  |                                              |
| <input type="checkbox"/> C-kit mutation (mast cell disease)               |                                              |

#### Hematopathology | AML-Related Molecular Tests (if positive for AML)

- |                                                                                  |                                         |
|----------------------------------------------------------------------------------|-----------------------------------------|
| <input type="checkbox"/> AML FLT3 and NPM mutation                               |                                         |
| <input type="checkbox"/> AML intermed risk cytogenetic reflex (CEBPA, IDH1/2)    |                                         |
| <input type="checkbox"/> IDH1 and IDH2 mutation                                  | <input type="checkbox"/> CEBPA Mutation |
| <input type="checkbox"/> FLT3 mutation                                           | <input type="checkbox"/> NPM Mutation   |
| <input type="checkbox"/> C-Kit mutation AML [reflex if t(8;21) (exons 8 and 17)] |                                         |

### Cytogenetics/FISH Analysis Request

**Cytogenetics testing/Conventional chromosome analyses (karyotyping) requested (must be completed to avoid delays in processing)**

- |                                                            |                                           |
|------------------------------------------------------------|-------------------------------------------|
| <input type="checkbox"/> Bone marrow chromosome study      |                                           |
| <input type="checkbox"/> Peripheral blood chromosome study |                                           |
| <input type="checkbox"/> Solid tumor chromosome study      | <input type="checkbox"/> Lymph node study |
| <input type="checkbox"/> Other chromosome study: _____     |                                           |

**FISH Analyses: For each probe, select the entire panel, or customize your own panel. If the probe is unspecified, contact the laboratory.**

AML (non-M3)	ALL	CLL/SLL	MM/PCL
<input type="checkbox"/> Panel (all listed) <input type="checkbox"/> BCR/ABL1 t(9;22) <input type="checkbox"/> KMT2A (MLL) <input type="checkbox"/> RUNX1/RUNX1T1 t(8;21) <input type="checkbox"/> CBFB (inv16)	<input type="checkbox"/> Panel (all listed) <input type="checkbox"/> BCR/ABL1 t(9;22) <input type="checkbox"/> KMT2A (MLL) <input type="checkbox"/> ETV6/RUNX1 t(12;21) <input type="checkbox"/> TCF3/PBX1 t(1;19) <input type="checkbox"/> 4cen/10cen	<input type="checkbox"/> Panel (all listed) <input type="checkbox"/> 13q- <input type="checkbox"/> ATM (del11q) <input type="checkbox"/> 12cen (trisomy 12) <input type="checkbox"/> TP53 (del17p)	<input type="checkbox"/> Panel (all listed) <input type="checkbox"/> CKSB1 (1q21 gain) <input type="checkbox"/> 13q- <input type="checkbox"/> TP53 (del17p) <input type="checkbox"/> IGH (14q32)* If IGH-positive, fusions as necessary.
<b>APL (M3)</b> <input type="checkbox"/> PML/RARA t(15;17)	<b>Non-Hodgkin's Lymphomas</b>		
<input type="checkbox"/> Panel (all listed) <input type="checkbox"/> 5q- <input type="checkbox"/> 7q- <input type="checkbox"/> 8cen (trisomy 8) <input type="checkbox"/> 20q-	<input type="checkbox"/> MYC <input type="checkbox"/> BCL6 <input type="checkbox"/> BCL2 <input type="checkbox"/> IGH/BCL2 t(14;18) <input type="checkbox"/> IGH/MYC t(8;14) <input type="checkbox"/> IGH/CCND1 t(11;14)	<input type="checkbox"/> IGH/FGFR3* t(4;14) <input type="checkbox"/> IGH/MAF* t(14;16) <input type="checkbox"/> IGH/CCND1* t(11;14) <input type="checkbox"/> IGH/MYC* t(8;14)	

#### FOR LAB USE ONLY

Lab #: \_\_\_\_\_

Test Codes: \_\_\_\_\_

Specimen Description: \_\_\_\_\_